Bictegravir, embitcitabine, and tenofovir alafenamide


Bictegravir, embitcitabine, and tenofovir alafenamide

Drug updated on 11/16/2023

Dosage FormTablet (oral; bictegravir/emtricitabine/tenofovir alafenamide: 50 mg/ 200 mg/ 25 mg); Tablet (oral; bictegravir/emtricitabine/tenofovir alafenamide: 30 mg/ 120 mg/ 15 mg)
Drug ClassAntivirals
Ongoing and Completed


  • Indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

Product Monograph / Prescribing Information

Document TitleYearSource
Biktarvy (bictegravir, embitcitabine, and tenofovir alafenamide) Prescribing Information.2022Gilead Sciences, Inc. Foster City, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines